JP2006153499A5 - - Google Patents

Download PDF

Info

Publication number
JP2006153499A5
JP2006153499A5 JP2004340765A JP2004340765A JP2006153499A5 JP 2006153499 A5 JP2006153499 A5 JP 2006153499A5 JP 2004340765 A JP2004340765 A JP 2004340765A JP 2004340765 A JP2004340765 A JP 2004340765A JP 2006153499 A5 JP2006153499 A5 JP 2006153499A5
Authority
JP
Japan
Prior art keywords
gtp
cancer
glutamyl
bone metastasis
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004340765A
Other languages
Japanese (ja)
Other versions
JP4572269B2 (en
JP2006153499A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2004340765A priority Critical patent/JP4572269B2/en
Priority claimed from JP2004340765A external-priority patent/JP4572269B2/en
Publication of JP2006153499A publication Critical patent/JP2006153499A/en
Publication of JP2006153499A5 publication Critical patent/JP2006153499A5/ja
Application granted granted Critical
Publication of JP4572269B2 publication Critical patent/JP4572269B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (18)

被検動物における癌の骨転移のリスクを予測する方法であって、
前記被検動物から得た生物学的試料におけるγ−グルタミルトランスペプチダーゼ（γ−ＧＴＰ）レベルを測定し、
該γ−ＧＴＰレベルが、癌の骨転移のある動物の生物学的試料におけるγ−ＧＴＰレベルを参照して予め設定された閾値よりも高い場合に、癌の骨転移のリスクが高いと予測することを特徴とする、方法。 A method for predicting the risk of bone metastasis of cancer in a test animal,
Measuring γ-glutamyltranspeptidase (γ-GTP) level in a biological sample obtained from the test animal,
A risk of cancer bone metastasis is predicted to be high if the γ-GTP level is higher than a preset threshold with reference to the γ-GTP level in a biological sample of an animal with cancer bone metastasis A method characterized by that. 前記生物学的試料が尿である、請求項１に記載の方法。   The method of claim 1, wherein the biological sample is urine. 前記生物学的試料が癌細胞である、請求項１に記載の方法。   The method of claim 1, wherein the biological sample is a cancer cell. 前記γ−ＧＴＰレベルの測定が、酵素免疫測定法（ＥＩＡ）、放射性免疫測定法（ＲＩＡ）、蛍光免疫測定法（ＦＩＡ）、エライザ法（ＥＬＩＳＡ）、免疫組織化学染色法、高速液体クロマトグラフィー定量法、酵素法、ウェスタン・ブロッティング法、ノーザン・ブロッティング法、またはＲＴ−ＰＣＲにより行われる、請求項１に記載の方法。   The γ-GTP level is measured by enzyme immunoassay (EIA), radioimmunoassay (RIA), fluorescent immunoassay (FIA), ELISA (ELISA), immunohistochemical staining, high performance liquid chromatography quantification. The method according to claim 1, wherein the method is performed by a method, an enzymatic method, a Western blotting method, a Northern blotting method, or RT-PCR. 前記癌が、乳癌、肺癌、前立腺癌、または胃癌である、請求項１に記載の方法。   The method of claim 1, wherein the cancer is breast cancer, lung cancer, prostate cancer, or stomach cancer. 前記閾値がＲＯＣ分析により設定される、請求項１に記載の方法。   The method of claim 1, wherein the threshold is set by ROC analysis. 癌と診断された動物において、癌の骨転移をモニタリングする方法であって、
前記動物から得た生物学的試料におけるγ−ＧＴＰレベルを測定することを含んでなり、
前記γ−ＧＴＰレベルが経時的に上昇したときに癌の骨転移のリスクが増加したとする、方法。 A method for monitoring bone metastasis of cancer in an animal diagnosed with cancer, comprising:
Measuring γ-GTP levels in a biological sample obtained from said animal,
A method wherein the risk of bone metastasis of cancer increases when the γ-GTP level increases with time. 前記生物学的試料が尿である、請求項７に記載の方法。   8. The method of claim 7, wherein the biological sample is urine. 前記生物学的試料が癌細胞である、請求項７に記載の方法。   8. The method of claim 7, wherein the biological sample is a cancer cell. γ−ＧＴＰの癌の骨転移マーカーとしての使用。   Use of γ-GTP as a bone metastasis marker for cancer. 前記γ−ＧＴＰが尿中γ−ＧＴＰである、請求項１０に記載の使用。   The use according to claim 10, wherein the γ-GTP is urinary γ-GTP. 前記γ−ＧＴＰが癌細胞から発現されるものである、請求項１０に記載の使用。   The use according to claim 10, wherein the γ-GTP is expressed from cancer cells. γ−ＧＴＰからなる、癌の骨転移マーカー。   A cancer bone metastasis marker comprising γ-GTP. 前記γ−ＧＴＰが尿中γ−ＧＴＰである、請求項１３に記載のマーカー。   The marker according to claim 13, wherein the γ-GTP is urinary γ-GTP. 前記γ−ＧＴＰが癌細胞から発現されるものである、請求項１３に記載のマーカー。   The marker according to claim 13, wherein the γ-GTP is expressed from a cancer cell. 少なくともγ−ＧＴＰレベル測定用試薬を含んでなる、癌の骨転移のリスクの診断用キット。   A diagnostic kit for risk of bone metastasis of cancer, comprising at least a reagent for measuring γ-GTP level. 前記γ−ＧＴＰレベル測定用試薬が、抗γ−ＧＴＰ抗体またはγ−ＧＴＰ活性測定用基質である、請求項１６に記載の診断用キット。   The diagnostic kit according to claim 16, wherein the reagent for measuring γ-GTP level is an anti-γ-GTP antibody or a substrate for measuring γ-GTP activity. 前記γ−ＧＴＰレベル測定用試薬が、抗γ−ＧＴＰモノクローナル抗体、Ｌ−γ−グルタミル−ｐ−ニトロアニリド、Ｌ−γ−グルタミル−３−カルボキシ−４−ニトロアニリド、Ｌ−γ−グルタミル−３−カルボキシ−４−ヒドロキシアニリド、Ｌ−γ−グルタミル−ｐ−Ｎ−エチル−Ｎ−ヒドロキシエチルアミノアニリド、Ｌ−γ−グルタミル−３，５−ジブロモ−４−ヒドロキシアニリド、Ｌ−γ−グルタミル−α−ナフチルアミン、またはＬ−γ−グルタミル−３−カルボキシ−１，４−フェニレンジアミンから選択される、請求項１６に記載の診断用キット。   The reagent for measuring γ-GTP level is an anti-γ-GTP monoclonal antibody, L-γ-glutamyl-p-nitroanilide, L-γ-glutamyl-3-carboxy-4-nitroanilide, L-γ-glutamyl-3. -Carboxy-4-hydroxyanilide, L-γ-glutamyl-pN-ethyl-N-hydroxyethylaminoanilide, L-γ-glutamyl-3,5-dibromo-4-hydroxyanilide, L-γ-glutamyl- The diagnostic kit according to claim 16, which is selected from α-naphthylamine or L-γ-glutamyl-3-carboxy-1,4-phenylenediamine.
JP2004340765A 2004-11-25 2004-11-25 How to predict the risk of bone metastasis of cancer Active JP4572269B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004340765A JP4572269B2 (en) 2004-11-25 2004-11-25 How to predict the risk of bone metastasis of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004340765A JP4572269B2 (en) 2004-11-25 2004-11-25 How to predict the risk of bone metastasis of cancer

Publications (3)

Publication Number Publication Date
JP2006153499A JP2006153499A (en) 2006-06-15
JP2006153499A5 true JP2006153499A5 (en) 2008-01-10
JP4572269B2 JP4572269B2 (en) 2010-11-04

Family

ID=36632000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004340765A Active JP4572269B2 (en) 2004-11-25 2004-11-25 How to predict the risk of bone metastasis of cancer

Country Status (1)

Country Link
JP (1) JP4572269B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603734B2 (en) * 2007-06-04 2013-12-10 The Johns Hopkins University Biomarkers for prostate cancer
EP2758057B1 (en) * 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis

Similar Documents

Publication Publication Date Title
Sharma et al. Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools
US10345309B2 (en) Biomarkers for gastric cancer and uses thereof
JP4896994B2 (en) Detection of cancer by elevated BCL-2 levels
DK1761651T3 (en) MNRA ratios in urinary sediments and / or urine as a prognostic and / or teranostic marker for prostate cancer
RU2009127774A (en) CANCER BIOMARKERS
JP2015505370A5 (en)
JP2009544007A (en) A method for prognosing cancer based on intracellular localization of biomarkers
JP2011504102A5 (en)
WO2007093657A2 (en) Method for the molecular diagnosis of prostate cancer and kit for implementing same
ES2579210T3 (en) NGAL as a biomarker for the activation of the mineralocorticoid receptor
RU2008101660A (en) METHOD FOR DIAGNOSTIC OF ALZHEIMER'S DISEASE
US20180238890A1 (en) Methods and materials for detection, diagnosis and management of ovarian cancer
CA2623653A1 (en) Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis
Huang et al. S100A4 over-expression underlies lymph node metastasis and poor prognosis in colorectal cancer
Sanchez-Carbayo Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens
EP2979096B1 (en) Integrin alpha-v-beta 6 for diagnosis/prognosis of colorectal carcinoma
JP2005523727A (en) How to detect tumor biomarkers and diagnose tumors
WO2012145399A2 (en) Methods of diagnosing cancer in a patient
JP2006153499A5 (en)
EP3545108A1 (en) Biomarkers for the prognosis and diagnosis of cancer
Xie et al. Expression of cysteine-rich 61 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma
WO2019115679A1 (en) A signature to assess prognosis and therapeutic regimen in liver cancer
EP2089546A4 (en) Methods of diagnosing osteoarthritis
Han ER, PR and HER2 testing in breast cancer
WO2020179712A1 (en) Methods for predicting tumor response to eribulin